Authors
Latest:
HER2-Targeted Therapy in Upper GI CancerSam Klempner, MD, provides insight on HER2-targeted therapy for patients with upper GI cancer, and the Oncology Brothers recap the entire discussion.
Latest:
Clinical Pearls on Treating Patients with NRG1 FusionsTeresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, offer key takeaways and conclude their discussion by offering advice for clinicians treating patients with NRG1 fusion–positive malignancies.
Latest:
Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic ReviewDanazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Latest:
Medical Education May Improve Care for Breast Cancer Minority PopulationsPhotographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
Latest:
Detecting High-Risk Prostate Cancer Factors Can Inform Referral StrategiesAn expert from Dana-Farber Cancer Institute indicates that urologists should refer patients with prostate cancer who present with multiple high-risk factors at surgery to a radiation and medical oncologist.
Latest:
Incentivizing RCC Research Investment Across Lower-Income CountriesGiven resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Latest:
Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIsDr. Judd W. Moul, MD, and colleagues present the case of a man, aged 73 years, with a prostate-specific antigen level of 110 ng/mL after 4 negative prostate biopsies and 4 negative prostate MRIs.
Latest:
Key Takeaways and Future in Advanced Gastric Cancer TreatmentPanelists discuss how future analyses in advanced gastric cancer should assess long-term survival, real-world outcomes, biomarkers for response, resistance mechanisms, and patient selection for nivolumab plus chemotherapy. Evaluating these factors will optimize treatment strategies and confirm its role across diverse populations.
Latest:
Conducting Early Phase Trials of Promising Treatments in Neuro-OncologyShwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.
Latest:
Fred Saad, MD, FRCS, Highlights Positive OS Trend With Abiraterone and Olaparib in mCRPC But Cites Need for Longer Follow-upAbiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.
Latest:
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural EffusionThis case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
Latest:
Uday R. Popat, MD, on the Future of Post-Transplant Cyclophosphamide to Prevent GVHD After Transplant for AML/MDSUday R. Popat, MD, spoke about where he sees future research efforts headed regarding post-transplant cyclophosphamide to prevent graft-vs-host disease for patients with acute myeloid leukemia after transplant and how these results could impact the standard of care.
Latest:
Leveraging Artificial Intelligence Evolutions in Prostate Cancer CareAI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.
Latest:
Avutometinib/Defactinib May be a New SOC in Low-Grade Serous Ovarian CancerInterim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Latest:
3 Things You Should Know About Immunotherapy in DLBCLHere are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.
Latest:
Key Takeaways on the Management of Clear-Cell RCCIn closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.
Latest:
Advanced Technology Will Help Drive Reimbursement ChangeAn industry through leader recaps current challenges to traditional reimbursement models for Medical Economics®.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
